Melissa Sherman, PhD

Chief Executive Officer

MOBILion Systems, Inc.

Melissa started her career as a research chemist with E.I. DuPont de Nemours and quickly transitioned from technical to marketing and business management positions in polymer fiber related industries.  After DuPont, she worked for W.L. Gore as a product manager overseeing product development, manufacturing, regulatory, and sales for a variety of surgical product businesses.

Melissa built an independent technology commercialization and strategy company, working with diverse clients in the regenerative medicine medical product sector.   She was hired by medical device companies, Kensey Nash and Aimago, to redefine and execute corporate growth strategies, leading both companies to successful exit via acquisition.

Melissa was the Director of Technology and Business Development for IP Group Inc. where she managed early-stage technology investment at federal laboratories and was responsible for investment thesis development, deal origination, due diligence, and transaction execution.  IP Group appointed Melissa to her current position as the CEO of MOBILion Systems Inc., an IP Group portfolio company.

Melissa has a Ph.D. in Polymer Science from The University of Akron, and a B.S. in Chemistry from The University of Wisconsin – Eau Claire.  Melissa, a Six Sigma Black Belt, will lead MOBILion into the future with her passion for building businesses, her visionary leadership, and her unmatched ability to execute tactically.

Sector Focus Breakout: Life Science

Discover IP Group, Inc.’s Life Science portfolio, with updates from two growing companies, MOBILion Systems Inc. and Carisma Therapeutics, as well as an introduction to one of IP Group’s exciting early-stage projects from the University of Pennsylvania.

Schedule a one-on-one meeting

If you are an investor or strategic interested in meeting with one of our portfolio companies one-on-one, please click here to speak with a member of the IP Group team. Please visit our website for more information on our growing portfolio.